Ehab Mohamed Khalil

Prof. Dr. Ehab Mohamed Khalil


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2006 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
MZMohamed Saad Zaghloul
Mohamed Saad Zaghloul
ANAkram Nouh
Akram Nouh
MNMohamed Nazmy
Mohamed Nazmy
SRSamy Ramzy
Samy Ramzy
AZAshraf S. Zaghloul
Ashraf S. Zaghloul
EKEhab Mohamed Khalil
Ehab Mohamed Khalil

1 March 2012 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
MNMohamed Soliman Nazmy
Mohamed Soliman Nazmy
YKYasser Khafaga
Yasser Khafaga
AMAmr Mousa
Amr Mousa
EKEhab Mohamed Khalil
Ehab Mohamed Khalil

1 December 2009 in Clinical Oncology
Verified
Journal Article
Closed access
MEM. El-Haddad
M. El-Haddad
MEM. El-Sebaie
M. El-Sebaie
RAR. Ahmad
R. Ahmad
EKEhab Mohamed Khalil
Ehab Mohamed Khalil
MSM. Shahin
M. Shahin
AAA. Allam
A. Allam

1 September 2016 in Journal of the Egyptian National Cancer Institute
Verified
Journal Article
Open access
CHChristine Higby
Christine Higby
YKYasser Khafaga
Yasser Khafaga
MAMohammad Al-Shabanah
Mohammad Al-Shabanah
AMAmr Mousa
Amr Mousa
MIMohamed Ilyas
Mohamed Ilyas
EKEhab Mohamed Khalil
Ehab Mohamed Khalil
To compare volumetric-modulated arc therapy (VMAT) with 3D-conformal radiation therapy (3D-CRT) mediastinal irradiation for stage I-II supra-diaphragmatic Hodgkin's Lymphoma (HL). Eleven patients were planned for RT after 4-6 cycles of ABVD chemotherapy: conventional 3D-CRT (AP/PA) and VMAT plans were conformed to the same PTV. Objective was to choose the best PTV coverage plan with the least OAR dose. The 2 plans were compared for: PTV coverage, mean dose and V5,V20lung, mean dose and V30heart, V5, V10, V15breast (female patients), and the integral body dose. Both techniques achieved adequate PTV coverage. Mean lung and heart dose was consistently lower in VMAT plans. The lung V20 dose was acceptable for VMAT, but exceeded the tolerance threshold in 6 cases with 3DCRT plans. A mean difference of 15.9% for both lungs V20 favored VMAT plans; average MLD difference was 2.3Gy less for VMAT plans. Similarly, lower maximum and mean heart doses with a 3.3Gy dose reduction and a 9.4% difference in V30 favored VMAT plans. Mean V5lung/female breast and integral dose were invariably higher in VMAT plans because of the low-dose spread. VMAT is a valuable technique for treatment of large mediastinal HL. VMAT spares the lung and heart compared to 3DCRT using ISRT in select HL cases. VMAT allows dose escalation for post-chemotherapy residual disease with minimal dose to OARs. VMAT low radiation dose (V5) to the normal tissues, and the increased integral dose should be considered.

1 September 2015 in Journal of the Egyptian National Cancer Institute
Verified
Journal Article
Open access
EKEhab Mohamed Khalil
Ehab Mohamed Khalil
MAManal M. Anwar
Manal M. Anwar
Radio-chemotherapy management for pediatric NPC resulted in comparable treatment outcomes with tolerable late effects. Response adapted radio-chemotherapy regimens in addition to the potential use of IMRT should be recommended to decrease treatment related side effects. Prolonged OAP of RT⩾50 days and low Hb level were encountered as adverse prognostic factors; findings that need further investigation.

24 February 2016 in Asia-Pacific Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
MZMohamed Saad Zaghloul
Mohamed Saad Zaghloul
EEEman Eldebawy
Eman Eldebawy
SASoha Ahmed
Soha Ahmed
HAHany Ammar
Hany Ammar
EKEhab Mohamed Khalil
Ehab Mohamed Khalil
AEAmr Elnashar
Amr Elnashar